WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on June 28, 2023, the compensation […]
Tag: Ardelyx
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 22, 2023, the compensation […]
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million “As we look towards the remainder of the year, we will continue to focus on achieving our near-term milestones, including driving IBSRELA adoption, preparing to launch XPHOZAH […]
FDA Grants Appeal for Ardelyx’s XPHOZAH® (tenapanor)
Office of New Drugs directs the Division of Cardiology and Nephrology to work with Ardelyx to develop a label to support the commercialization of XPHOZAH; Ardelyx to resubmit NDA in the first half of 2023 Upon approval, XPHOZAH would be […]
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass., Nov. 3, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates […]
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass., Aug. 4, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and […]
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., July 1, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on June 28, 2022, the compensation committee of the […]
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
Conference Call Scheduled for 4:30 PM Eastern Time Today WALTHAM, Mass., May 5, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today provided a business […]
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., April 12, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on April 5, 2022, the compensation committee of the […]
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., March 9, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on March 4, 2022, the compensation committee of the […]